Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Endoxifen for Mammographic Breast Density
NCT04616430Phase 2Completed
- Sponsor
- Atossa Therapeutics
- Start
- Apr 2018
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of z-endoxifen in breast cancer (3 arms), sponsored by Atossa Therapeutics. Primary endpoint: Change in Mammographic Breast Density At Study Exit at 6 months. Started Apr 2018; status: completed.
02
Drugs
z-endoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04616430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616430.